

# SEMMERING IV: Vaccines in the light of immune therapy and therapeutic antibodies, April 23-25, 2009

## PROGRAM

---

**Thursday, April 23**

---

### Opening

15:00 – 15:15 Alexander VON GABAIN, Intercell AG, Vienna, Austria  
*Welcome address*

### Session I: Needed vaccines

15:15 – 15:45 Heikki PELTOLA, HUCH Hospital for Children and Adolescents, Helsinki, Finland  
*Existing new vaccines in children - a critical view*

15:45 – 16:15 Rino RAPPUOLI, Novartis Vaccines, Siena, Italy  
*Towards a MenB vaccine*

16:15 – 16:45 John VEKEMANS, GlaxoSmithKline Biologicals, Rixensart, Belgium  
*The RTS,S/AS malaria candidate vaccine: on the eve of Phase III*

16:45 – 17:15 Jerald SADOFF, AERAS Global TB Vaccine Foundation, Rockville, Maryland, USA  
*TB Vaccine Development*

17:15 – 17:45 Martin FRIEDE, World Health Organization, Geneva, Switzerland  
*Developing vaccines for neglected diseases*

17:45 – 18:00 *Afternoon break*

### Opening of the poster session and get together

18:00 Opening of the poster session and aperitifs

19:00 Dinner

PRISMA  
www.prisma-zentrum.com

Parteurop

HUMALIS

ERSTE

gsk  
GlaxoSmithKline  
Biologicals

TVM | Capital

Boehringer  
Ingelheim

austrian  
council

lisa  
Life Science Austria  
Vienna Region

intercell  
SMART VACCINES

Merrill Lynch

Crucell

MSD  
charles river  
accelerating drug development. exactly.

NOVARTIS

BMW<sub>F</sub><sup>a</sup>

# SEMMERING IV: Vaccines in the light of immune therapy and therapeutic antibodies, April 23-25, 2009

## PROGRAM

Friday, April 24

### Morning Session:

8:30 – 09:00 Ulrich HEININGER, University Children's Hospital (UKBB) Basel, Basel, Switzerland  
*A risk/benefit analysis of vaccines*

### Session II: Finding the target

09:00 – 09:30 Alessandro SETTE, La Jolla Institute for Allergy and Immunology, San Diego California, USA  
*Predicting vaccine antigens*

09:30 – 10:00 Felix REY, Institut Pasteur, Paris, France  
*Crystal structures the dengue virus envelope protein in complex with neutralizing antibody fragments*

10:00 – 10:30 Adnane ACHOUR, Karolinska Institutet, Stockholm, Sweden  
*Development of a novel generation of MHC class I-binding super-peptides for vaccines*

10:30 – 11:00 Morning break

### Session III: Microbes, genomes, evolution and microbiomics

11:00 – 11:30 Antoine DANCHIN, Institut Pasteur, Paris, France  
*Natural selection and immortality*

11:30 – 12:00 Birgitta HENRIQUES-NORMARK, Swedish Institute for Infectious Disease Control, Dept. of Bacteriology, Solna, Sweden  
*Epidemiology of Pneumococcus*

12:00 – 12:30 Thomas MEYER, Max-Planck-Institut für Infektionsbiologie, Berlin, Germany  
*Vaccination against Helicobacter pylori and the targeting of host cell functions  
as an immune-modulatory approach*

PRISMA  
www.prisma-zentrum.com

Parteurop

HUMALIS

ERSTE

gsk  
GlaxoSmithKline  
Biologicals

TVM | Capital

Boehringer  
Ingelheim

austrian  
council

lisa  
Life Science Austria  
Vienna Region

intercell  
SMART VACCINES

Merrill Lynch

Crucell

MSD  
charles river  
accelerating drug development. exactly.

NOVARTIS

BMWF<sup>a</sup>

# SEMMERING IV: Vaccines in the light of immune therapy and therapeutic antibodies, April 23-25, 2009

## PROGRAM

12:30 – 13:00 Joël DORE, INRA, Paris, France  
*Human intestinal microbiomics in health and disease*

13:00 – 14:30 *Lunch break*

---

### Friday, April 24 (continued)

---

#### Session IV: Study of the immune response

14:30 – 15:00 Thomas DECKER, Max F. Perutz Laboratories, Vienna, Austria  
*Type I interferons: innate cytokines and regulators of adaptive immunity*

15:00 – 15:30 Claude LECLERC, Institut Pasteur, Paris, France  
*Therapeutic vaccination against large established tumors by a new delivery system targeting dendritic cells*

15:30 – 16:00 Adrian HAYDAY, Kings College, London, United Kingdom\*  
*The role of T-gamma and -delta cells*

16:00 – 16:30 Reinhold FOERSTER, Hannover Medical School, Institute of Immunology, Hannover, Germany  
*CCR7 as a key regulator for lymph node homeostasis*

16:30 – 18:00 *Afternoon break*

#### Social program and dinner

18:00 Social program

PRISMA  
www.prisma-zentrum.com

Parteurop

HUMALIS

ERSTE

gsk  
GlaxoSmithKline  
Biologicals

TVM | Capital

Boehringer  
Ingelheim

austrian  
council

lisa  
Life Science Austria  
Vienna Region

intercell  
SMART VACCINES

Merrill Lynch

Crucell

MSD  
charles river  
accelerating drug development. exactly.

NOVARTIS

BMWF<sup>a</sup>

# SEMMERING IV: Vaccines in the light of immune therapy and therapeutic antibodies, April 23-25, 2009

## PROGRAM

19:00 Dinner

---

**Saturday, April 25**

---

### Session V: mAbs in infectious diseases

08:30 – 09:00 Peter LACHMANN, Cambridge University, Cambridge, United Kingdom  
*Passive Immunisation against Infectious Disease – an old paradigm revisited*

09:00 – 09:30 Arturo CASADEVALL, Albert Einstein College of Medicine, New York, USA  
*Anti-infective AB strategies*

09:30 – 10:00 Eszter NAGY, Intercell AG, Vienna, Austria  
*Group B Streptococcus Prevention Strategy Based on Monoclonal Antibodies*

**10:00 – 10:30 Morning break**

10:30 – 11:00 Fons UYTDEHAAG, Crucell, Leiden, Netherlands  
*Recognition of a highly conserved epitope across influenza virus subtypes by a influenza virus neutralizing human monoclonal antibody*

11:00 – 11:30 Ulrich KALINKE, Twincore Centre of Experimental and Clinical Infection Research, Hannover, Germany  
*TGN1412: Lessons Learnt*

11:30 – 12:00 James E. CROWE, Jr., Vanderbilt University, Nashville, Tennessee, USA  
*Human antibodies that neutralize pandemic influenza viruses*

**12:00 – 13:30 Lunch break**

PRISMA  
www.prisma-zentrum.com

Parteurop

HUMALIS

ERSTE

gsk  
GlaxoSmithKline  
Biologicals

TVM | Capital

Boehringer  
Ingelheim

austrian  
council

lisa  
Life Science Austria  
Vienna Region

intercell  
SMART VACCINES

Merrill Lynch

Crucell

MSD  
charles river  
accelerating drug development. exactly.

NOVARTIS

BMW<sub>F</sub><sup>a</sup>

# SEMMERING IV: Vaccines in the light of immune therapy and therapeutic antibodies, April 23-25, 2009

## PROGRAM

### Session VI: Therapeutic cancer vaccines

- 13:30 – 14:00 Michael T. LOTZE, University of Pittsburgh, Pittsburgh, Pennsylvania, USA  
*Damage Associated Molecular Pattern Molecules [DAMPs] Promote Immune Responses*
- 14:00 – 14:30 Martin KAST, University of Southern California, Los Angeles, California, USA  
*A new therapeutic vaccine induces lifelong protection from prostate cancer*
- 14:30 – 15:00 Melvyn LITTLE, Affimed Therapeutics, Heidelberg, Germany  
*TandAbs for recruiting NK-cells and T-cells to kill tumor cells*

15:00 – 15:30 *Afternoon break*

---

### Saturday, April 25 (continued)

---

### Session VII: Diarrheal diseases

- 15:30 – 16:00 Gregory GLENN, Intercell USA., Gaithersburg, Maryland, USA  
*The vaccine patch containing heat-labile toxin from Escherichia coli for protection against travelers' diarrhoea*
- 16:00 – 16:30 Armelle PHALIPON, Institut Pasteur, Paris, France  
*Towards a Shigella vaccine: dream or reality?*
- 16:30 – 17:00 Florian SCHODEL, Merck & Co. Inc., West Point, Pennsylvania, USA  
*The Pentavalent Rotavirus Vaccine, RotaTeq™: From Development to Licensure and Beyond*

PRISMA   
www.prisma-zentrum.com

 Parteurop

 HUMALIS

ERSTE 

 gsk  
GlaxoSmithKline  
Biologicals

TVM | Capital

 Boehringer  
Ingelheim

 austrian  
council

 lisa  
Life Science Austria  
Vienna Region

 intercell  
SMART VACCINES

 Merrill Lynch

 Crucell

 MSD  
charles river  
accelerating drug development. exactly.

 NOVARTIS

 BMW\_F<sup>a</sup>

# SEMMERING IV: Vaccines in the light of immune therapy and therapeutic antibodies, April 23-25, 2009

## PROGRAM

### Closing session: The need of new vaccines

17:00 – 17:30 Jean STEPHENNE, GlaxoSmithKline Biologicals, Wavre, Belgium  
*The need of new vaccines*

17:30 – 18:00 Alexander VON GABAIN, Intercell AG, Vienna, Austria  
*Closing remarks*

*18:00 – 19:00 Afternoon break*

### Gala evening

19:00 Aperitifs

19:30 Dinner

PRISMA   
www.prisma-zentrum.com

 Parteurop

 HUMALIS

ERSTE 

 gsk  
GlaxoSmithKline  
Biologicals

TVM | Capital

 Boehringer  
Ingelheim

 austrian  
council

 lisa  
Life Science Austria  
Vienna Region

 intercell  
SMART VACCINES

 Merrill Lynch

 Crucell

 MSD  
charles river  
accelerating drug development. exactly.



NOVARTIS

BMWF<sup>a</sup>